

**AMENDED NOTICE
NATIONAL INSTRUMENT 51-102
CHANGE OF CORPORATE STRUCTURE**

This amended notice is provided pursuant to the requirements of Section 4.9 of National Instrument 51-102 – *Continuous Disclosure Obligations* (“**NI 51-102**”) and amends and restates the Company’s previous notice dated and filed on May 31, 2021.

Item 1: Names of the Parties to the Transaction

Yuntone Capital Corp. (the “**Company**”)

Mantaro Silver Corp. (“**Mantaro**”)

Item 2: Description of the Transaction

On May 21, 2021, the Company completed its acquisition of Mantaro pursuant to the terms of an amalgamation agreement dated October 23, 2020, among the Company, Mantaro and a subsidiary of the Company. Each holder of a Mantaro common share received one (1) post-Consolidation common share of the Company (a “**Resulting Issuer Share**”) for each Mantaro common share held. All currently outstanding convertible securities of Mantaro, specifically Mantaro warrants were exchanged or replaced with Resulting Issuer warrants based on a 1:1 ratio and on the same economic terms and conditions as previously issued.

A total of 26,311,145 Resulting Issuer Shares were issued to the Mantaro Shareholders. After completion of the Transaction, the Mantaro securityholders became securityholders of the Company.

In conjunction with closing of the Transaction, the Company completed a consolidation on the basis of two pre-consolidation common shares of the Company were exchanged for one post-consolidation common share of the Company (the “**Consolidation**”). The Company also changed its name to Mantaro Silver Corp. on closing of the Transaction (the “**Name Change**”).

Mantaro previously completed a non-brokered private placement, of 23,576,652 subscription receipts (each a “**Subscription Receipt**”) at a price of \$0.35 per Subscription Receipt for gross proceeds of \$8,251,828.50 (the “**Concurrent Private Placement**”).

As a result of closing of the Transaction, each Subscription Receipt automatically converted into one common share of Mantaro (an “**Underlying Share**”) and one-half of one share purchase warrant of Mantaro (an “**Underlying Warrant**”). Pursuant to the Amalgamation Agreement, the Underlying Shares and Underlying Warrants were exchanged into Resulting Issuer Shares and common share purchase warrants of the Company (“**Resulting Issuer Warrants**”). Each Resulting Issuer Warrant is exercisable into a Resulting Issuer Share at an exercise price of \$0.55 until May 21, 2022.

Under the Concurrent Private Placement, Mantaro paid a cash commission of \$298,810 to eligible finders and issued a total 943,407 non-transferable common share purchase warrants (each an “**Broker Warrant**”). Each Broker Warrant will be exercisable into one Resulting Issuer Share at a price of \$0.55 for a period of one year from the date of issue.

Mantaro also completed a non-brokered private placement financing of 1,072,142 units (each a “**Unit**”) at a price of \$0.35 per Unit for total proceeds of \$375,250.25 (the “**Unit Financing**”). Each Unit consists of one common share of Mantaro and one-half of one share purchase warrant, with each whole warrant entitling the holder to purchase a common share of Mantaro at a price of \$0.55 per share for a period of twelve months from the date of closing. As a result of closing of the Amalgamation Agreement, shares and warrants issued under the Concurrent Financing and the Unit Financing were exchanged for Resulting Issuer Shares and Resulting Issuer Warrants.

Item 3: Effective Date of the Transaction

The effective date of the transaction is determined to be May 21, 2021.

Item 4: Names of Each Party that Ceased to be a Reporting Issuer Subsequent to the Transaction and Each Continuing Entity

Not applicable.

Item 5: Date of the Reporting Issuer's First Financial Year-End Subsequent to the Transaction

Mantaro is the reverse takeover acquirer. Accordingly, the financial year end of the Company will be February 28 and the next financial year end will February 28, 2022.

Item 6: Periods of the Interim and Annual Financial Statements Required to be Filed for the Reporting Issuer's First Financial Year Subsequent to the Transaction

The Company's filings that will occur subsequent to the transaction are as follows:

Financial Statements	Period Ended	Comparative Period Ended
Interim	May 31, 2021	May 31, 2020
Interim	August 31, 2021	August 31, 2020
Interim	November 30, 2021	November 30, 2020
Annual	February 28, 2022	February 28, 2021

Item 7: Documents Filed Under this Instrument Describing the Transaction

News release filed on May 28, 2021.

Material Change Report filed on May 31, 2021.

TSX Venture Exchange Filing Statement filed on May 12, 2021.

DATED this 3rd day of August, 2021

MANTARO SILVER CORP.

"Dr. Christopher Wilson"

Per: _____
Dr. Christopher Wilson, CEO